Literature DB >> 16418940

[Ocular involvement in MuSK antibody-positive myasthenia gravis].

V Bau1, F Hanisch, B Hain, S Zierz.   

Abstract

BACKGROUND: Antibodies (Ab) against the acetylcholine receptor (AChR) are found in 80 - 90 % of generalized myasthenia gravis (MG), but only in 50 % of pure ocular MG. Furthermore, Ab against the muscle-specific receptor tyrosine kinase (MuSK) were detected in 38 - 54 % of patients with AChR-Ab-negative ("seronegative") MG, but not in pure ocular MG.
METHODS: 2 case reports have been analysed: two patients (42 years old and 61 years old) with primary ocular MG were studied. Both patients complained of fluctuating bilateral ptosis and double vision lasting for 2 to 3 months.
RESULTS: AChR-Ab were negative but MuSK-Ab were clearly positive. In spite of treatment with pyridostigmine and prednisolone, the symptoms in patient 1 generalized within 4 weeks causing dysphagia, limb muscle weakness and respiratory crisis. Symptoms immediately responded to plasmapheresis. Patient 2 clearly improved under treatment with pyridostigmine, methylprednisone, and azathioprine. There was no generalization within a course of 12 months.
CONCLUSIONS: Both cases clearly indicate that MuSK-Ab can be found in primary isolated ocular MG lasting for 2 to 3 months. In a primary ocular manifestation of MG the detection of MuSK might indicate the risk for subsequent generalization and might have implications for immunosuppressive therapy. Therefore, seronegative MG requires testing for MuSK-Ab.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418940     DOI: 10.1055/s-2005-858629

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  4 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy.

Authors:  Jane W Chan; William W Orrison
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

Review 3.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

4.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.